Inhibrx Biosciences, Inc. Cash Flow-to-Debt Ratio
Inhibrx Biosciences, Inc. cash flow-to-debt ratio. Inhibrx Biosciences, Inc. (INBX) has a Cash Flow-to-Debt Ratio of -0.19x as of March 2026, meaning its operating cash flow of $-38.03 Million could theoretically repay 0% of its total liabilities ($205.00 Million) in one year. Check Inhibrx Biosciences, Inc. (INBX) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Inhibrx Biosciences, Inc. (2016–2025)
Cash flow-to-debt ratio of Inhibrx Biosciences, Inc. from 2016 to 2025. Historical debt coverage capacity for Inhibrx Biosciences, Inc. across 10 annual periods. Also explore INBX net assets growth trend to track the company's year-over-year net asset growth rate.
Inhibrx Biosciences, Inc. Cash Flow-to-Debt Ratio by Year (2016–2025)
Inhibrx Biosciences, Inc. cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Inhibrx Biosciences, Inc.. For the full cash flow conversion analysis, see Inhibrx Biosciences, Inc. operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.94x | $-129.79 Million | $138.49 Million | ▲ +77.3% |
| 2024 | -4.12x | $-194.41 Million | $47.18 Million | ▼ -463.5% |
| 2023 | -0.73x | $-193.31 Million | $264.39 Million | ▼ -47.6% |
| 2022 | -0.50x | $-115.30 Million | $232.82 Million | ▲ +39.5% |
| 2021 | -0.82x | $-80.32 Million | $98.07 Million | ▼ -16.6% |
| 2020 | -0.70x | $-47.97 Million | $68.27 Million | ▼ -163.0% |
| 2019 | -0.27x | $-32.08 Million | $120.06 Million | ▲ +21.7% |
| 2018 | -0.34x | $-23.09 Million | $67.63 Million | ▲ +27.8% |
| 2017 | -0.47x | $-18.75 Million | $39.67 Million | ▲ +47.7% |
| 2016 | -0.90x | $-18.11 Million | $20.03 Million | — |